Abstract

The goal of the study was to evaluate the impact of antiretroviral therapy (ART) on the semen characteristics in HIV-infected men.Materials and methods. A prospective case-control study enrolled 66 HIV-infected male patients who presented for fertility assessment. Group 1 included 51 male patients treated with ART; Group 2 included 15 males who were not receiving ART. 97 and 25 semen samples were analyzed, respectively. HIV status was assessed based on the data regarding the stage and phase of the disease, viral load, CD3+, CD4+, CD8+ counts and the ART duration.Study results. At enrollment in the study, the duration of HIV infection in Group 1 was longer than that in Group 2 (the difference being statistically significant): 5 years (2–9 years) versus 2,5 years (0,4–4,5), respectively (р=0,0004). Median duration of treatment in Group 1 was 1,5 years. The most common type of abnormal semen morphology in ART-treated patients was teratozoospermia (40%), and the percentage of abnormally shaped spermatozoa in this group was higher compared to Group 2 (the difference being statistically significant): 97 (96–98) versus 96 (94,5–96,5); р=0,006). Group 1 demonstrated a negative relationship between the count of abnormally shaped spermatozoa and CD4+ cell count (r=–0,362; р=0,026), disease duration (r=0,173; р=0,173) and sperm count (r=–0,242; р=0,020), progressively motile (category B) sperm count (r=–0,241; р=0,024). The ART duration showed an inverse correlation with the progressively motile sperm count (category B) (r=–0,224; р=0,036). Group 2 demonstrated a statistically significant positive relationship between the CD4+ cell count, the semen volume (r=0,778; p=0,014), and the count of progressively motile (category B) spermatozoa (r=0,667; р=0,05). We also revealed a statistically significant inverse relationship between the viral load and the semen volume (r=–0,669; р=0,035). Sperm DNA fragmentation was found to be higher in HIV-infected patients treated with ART compared to HIV-infected men not receiving ART (15,8% (12,4–23,0) and 14% (10,9–20,5); р=0,533), respectively. Thus, HIV-infected patients treated with ART demonstrated abnormal sperm morphology (increased abnormal sperm count), decreased sperm motility and increased sperm DNA fragmentation level. The percentage of abnormally shaped sperm was higher in patients with lower CD4+ cell counts. In patients with a long history of HIV infection, the sperm count decreases and the count of immotile spermatozoa increases. HIV-infected individuals who are not receiving ART and have high viral loads show decreased semen volume. This value increases upon an increase in the CD4+ cell count.

Highlights

  • Цель: оценить влияние антиретровирусной терапии на показатели спермограммы у мужчин, инфицированных вирус иммунодефицита человека (ВИЧ)

  • В группе пациентов, принимающих антиретровирусной терапии (АРВТ), в структуре патозооспермии преобладала тератозооспермия (40%), доля патологических форм сперматозоидов в данной группе была статистически значимо выше по сравнению со 2 группой: 97 (96–98) и 96 (94,5–96,5), р=0,006)

  • The most common type of abnormal semen morphology in antiretroviral therapy (ART)-treated patients was teratozoospermia (40%), and the percentage of abnormally shaped spermatozoa in this group was higher compared to Group 2: 97 (96–98) versus 96 (94,5–96,5); р=0,006)

Read more

Summary

Introduction

Цель: оценить влияние антиретровирусной терапии на показатели спермограммы у мужчин, инфицированных ВИЧ. Во 2 группе пациентов была выявлена статистически значимая положительная взаимосвязь между уровнем СD4+ лимфоцитов, объемом эякулята (r=0,778; p=0,014) и количеством прогрессивно-подвижных сперматозоидов категории В (r=0,667; р=0,05). При оценке процента фрагментации ДНК сперматозоидов было выявлено, что данный показатель был выше у ВИЧ-инфицированных пациентов, принимающих АРВТ по сравнению с ВИЧ-положительными мужчинами, не использовавшими терапию (15,8% (12,4–23) и 14% (10,9–20,5); р=0,533) соответственно.

Objectives
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.